



Hematologic Cancers: CLL/SLL

Challenging Cases in... Hematologic Cancer: CLL/SLL

Program conducted: February – April 2025

Note: Aggregated results and high-level summary based on 5 practices (≤40 HCPs) and do not necessarily reflect the views and opinions of the moderator or Cornerstone Specialty Network unless otherwise stated. Clinical data, NCCN Guidelines, and FDA approvals current at time of each presentation.

Report finalized: May 15, 2025

Participating Practices

- Fort Wayne Medical Oncology and Hematology (n=6) February 5, 2025
- Ironwood Cancer and Research Centers (n=8)
 February 12, 2025
- Northwestern Medicine (n=7)
 March 5, 2025
- Live Regional Exchange Atlanta (n=14)
 March 28, 2025
- Ironwood Cancer and Research Centers (n=5)
 April 22, 2025

Cornerstone Specialty Network, LLC

High-level Summary

Challenging Cases in... Hematologic Cancers:

CLL/SLL



- In general, first-line treatment choice was zanubrutinib, followed by acalabrutinib with or without obinutuzumab, or venetoclax with obinutuzumab.
 - First-line (1L) treatment preference is influenced by risk, treatment goals, and other patient factors.
 - Some indicated that venetoclax-based therapy was avoided upfront in high-risk patients (TP53 mutation or 17p deletion); reserved for later-lines.
 - Some noted clinical trial efficacy data reinforce confidence in BTK inhibitors (BTKi) upfront.
- If acalabrutinib is used in the 1L setting , then zanubrutinib is the preferred 2L treatment option followed by venetoclax with rituximab or venetoclax with obinutuzumab.
 - Some indicated choice is often guided by patient preference, previous tolerability, and the presence of resistance mutations.
 - Awareness of clinical trial data can influence treatment decisions.
- In general, dose interruption and restarting treatment at a lower dose was viewed as the best strategy to manage intolerance in patients with CLL.
 - Some noted if side effects persisted switching BTK inhibitor was considered an appropriate option only if no BTKi resistance mutation was detected.
 - Some test for BTKi resistance mutations, even in intolerance cases, to better guide next therapy.
 - Some consider switching to a different mechanism of action for patients with confirmed resistance or intolerable toxicities.

Cornerstone Specialty Network, LLC

High-level Summary

Challenging Cases in... Hematologic Cancers:

CLL/SLL



- In general, most indicated that they would be more likely to switch to a different irreversible (covalent) BTKi for a patient intolerant to a prior BTKi.
 - Some indicated if BTKi resistant mutations are detected then more likely to switch to venetoclax-based regimen.
- In general, venetoclax plus rituximab is the preferred treatment after 2L zanubrutinib therapy.
 - Some considered pirtobrutinib (a non-covalent BTKi) for patients who failed both a covalent BTKi and venetoclax in the 3L setting
- Comorbidities can play a role in determining utilization of a BTKi vs CAR T-cell therapy in the 3L setting.
- CAR T-cell therapy can have additional challenges within the community setting such as lengthy travel distances to treatment centers and or the need for caregiver support which may not be available.
- Some indicated referring patients for CAR T-cell therapy, especially if younger, fit patients with limited options in the 3L setting.

Cornerstone Specialty Network, LLC

Challenging Cases in... Hematologic Cancers



Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

What is the optimal first line therapy for patients? Second line therapy?

> How do adverse events impact treatment decisions?

How does intolerance impact subsequent treatment decisions?

Cornerstone Specialty Network, LLC

72-year-old male

Symptoms:

Lymphadenopathy in the neck and axillary region; increased infections

Comorbidities:

Past medical history of hyperlipidemia (taking statin) and chronic back pain CLL involvement with 80 % of the bone marrow

Diagnosis

Bone marrow cytogenetics showed trisomy 12 and t(y;8);

With del(17p)/TP53 mutation


Rai Stage 2 disease

What first-line treatment do you recommend?



ARS Results from HCP Participants

What first-line treatment do you recommend?






Cornerstone Specialty Network, LLC Confidential – Not for Distribution

n=23



NCCN Guidelines 1L setting | Version 3.2025 | April 2, 2025



COMPARISON 1L CLL/SLL

	ELEVATE-TN (Acalabrutinib)		CLL14 (Venetoclax)		SEQUOIA (Zanubrutinib)			
FDA Indication	CALQUENCE is indicated for the treatment of adult patients with CLL/SLL			VENCLEXTA is indicated for the treatment of adult patients with CLL/SLL		BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with CLL/SLL		
Study Design	Randomized, multicenter, open-label study of acalabrutinib ± obinutuzumab in Patients (Pts) With Treatment-Naive CLL/SLL			A fixed duration regimen of venetoclax + obinutuzumab for 1 year in Patients (Pts) With Treatment-Naive CLL/SLL		Zanubrutinib vs Bendamustine + Rituximab (BR) in Patients (Pts) With Treatment-Naive CLL/SLL		
	Randomized 1:1:1 (N=535) with del(17p): 10% vs 9% vs 10%			Randomized 1:1 (N=432) with del(17p): 9% vs 7%		Randomized without d	. ,	(n=110) with del(17p)
Long term follow-up	~6-year follow-up (median 74.5 months)			~6-year follow-up (median 76.4 months)		~5 year follow up (median 61.2 months)		~4 year follow up (median 43.7 months)
	Acalabrutinib + obinutuzumab	Acalabrutinib monotherapy	Obinutuzumab + Chlorambucil (GClb)	Venetoclax + Obinutuzumab	Obinutuzumab + Chlorambucil (GClb)	Zanubrutinib	Vs BR	Zanubrutinib
Primary endpoint:	HR= 0.14 ; 95% CI: 0.10-(78%	0.20 62%	17%	53%	22%	75.8%	40.1%	79%

VENCLEXTA® (venetoclax tablets) AML & CLL/SLL The BRUKINSA® Difference | BRUKINSA® (zanubrutinib) Treatment HCP Site (venclextahcp.com)

HR: 0.29 (95% CI 0.21 - 0.40)



PFS (%)

Reference



BTK Inhibitor for Adult Patients with CLL or SLL| CALQUENCE®

(acalabrutinib) 100 mg tablets (calquencehcp.com)

HR=**0.24**; 95% CI: 0.17-0.32

Considering the number of patients with del(17p) in each study, does that impact your treatment decision in the 1L setting?

HR=0.40; 95% CI: 0.31-0.52

70-year-old male Patient has an active and independent lifestyle

History of hypertension, otherwise healthy Initial treatment: Acalabrutinib

treatment

Prior 1

Myalgias increased Experienced headaches Neutropenia How do you typically manage intolerance?



How do you typically manage intolerance?

Dose interrupt until side effects resolve and then 61% restart treatment at a lower dose Dose reduce and continue treatment 22% Discontinue treatment and switch to a different 13% **BTKi therapy** Discontinue treatment and switch to a different 4% class of therapy Other 0% Unsure 0% n=23

Cornerstone Specialty Network, LLC

70-year-old male Patient has an active and independent lifestyle

History of hypertension, otherwise healthy <u>Initial treatment:</u> Acalabrutinib

treatment

Prior -


Myalgias increased Experienced headaches Neutropenia

Stopped treatment due to intolerance

What treatment do you recommend next?

cornersione specialty network

What is your treatment strategy after first-line acalabrutinib therapy?



cornerstone speciality network **Cornerstone Specialty Network, LLC** Confidential – Not for Distribution




NCCN Guidelines 2L+ setting

NCCN NCCN Network®

Comprehensive NCCN Guidelines Version 3.2025

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCCN Guidelines Index Table of Contents Discussion



Venetoclax ± anti-CD20 mAb (obinutuzumab preferred) is a treatment option for relapse after a period of remission.



Comprehensive Cancer Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCCN Guidelines Index Table of Contents Discussion

SUGGESTED TREATMENT REGIMENS^{a,b,c,d} CLL/SLL With del(17p)/*TP53* Mutation (alphabetical by category) CIT is not recommended since del(17p)/*TP53* mutation is associated with low response rates.


SECOND-LINE OR SUBSEQUENT THERAPY ^e							
Preferred Regimens	Other Recommended Regimens						
 BCL2i-containing regimen Venetoclax^{f,h,*} ± obinutuzumab cBTKi-based regimens Acalabrutinib^{f,g,p} (category 1) Zanubrutinib^{f,g,p} (category 1) ncBTKi-based regimen: Pirtobrutinib (resistance or intolerance to prior cBTKi-based regimens) 	 BCL2i-containing regimens Venetoclax^{f,h} + rituximab (category 1) Venetoclax^{f,h} + ibrutinib^{f,g,q} (category 2B) cBTKi-based regimen Ibrutinib^{f,g,i} (category 1) 						

* Venetoclax ± anti-CD20 mAb (obinutuzumab preferred) is a treatment option for relapse after a period of remission.

© 2025 Cornerstone Specialty Network. All rights reserved.

NCCN Guidelines CLL/SLL <u>with</u> del(17p)/TP53 mutation

How will the challenging case impact your prescribing behavior for a patient intolerant to a prior BTKi?



Cornerstone Specialty Network, LLC

70-year-old male Patient has an active and independent lifestyle

History of hypertension, otherwise healthy <u>Initial treatment:</u> Acalabrutinib


Prior treatment

Stopped treatment due to intolerance

Second line treatment: Zanubrutinib What treatment do you recommend next?



What is your treatment strategy after second-line zanubrutinib therapy?



cornerstone specialty network **Cornerstone Specialty Network, LLC** Confidential – Not for Distribution

NCCN Guidelines: Therapy for relapsed or refractory disease after prior **BTKi- and Venetoclax-based regimens**

On December 1, 2023, the

(Jaypirca, Eli Lilly and

inhibitor and a BCL-2

inhibitor.


maraleucel (liso-cel;

Brevanzi) for the

treatment of adult

who have previously

2 inhibitor.



and BCL-2 inhibitor

Key Takeaways



CLL/SLL

- Awareness of multiple category 1 NCCN Guideline treatments provides options for patients
 - Lack of head-to-head trials
- New FDA approvals and NCCN Guidelines will play a pivotal role in directing treatment pathways
- Mindfulness of clinical trial data can provide support for the best sequence of therapies and improve outcomes for patients

Cornerstone Specialty Network, LLC